Literature DB >> 24858853

Diverse forms of pulmonary hypertension remodel the arterial tree to a high shear phenotype.

Roblee P Allen1, Edward S Schelegle2, Stephen H Bennett3.   

Abstract

Pulmonary hypertension (PH) is associated with progressive changes in arterial network complexity. An allometric model is derived that integrates diameter branching complexity between pulmonary arterioles of generation n and the main pulmonary artery (MPA) via a power-law exponent (X) in dn = dMPA2(-n/X) and the arterial area ratio β = 2(1-2/X). Our hypothesis is that diverse forms of PH demonstrate early decrements in X independent of etiology and pathogenesis, which alters the arteriolar shear stress load from a low-shear stress (X > 2, β > 1) to a high-shear stress phenotype (X < 2, β < 1). Model assessment was accomplished by comparing theoretical predictions to retrospective morphometric and hemodynamic measurements made available from a total of 221 PH-free and PH subjects diagnosed with diverse forms (World Health Organization; WHO groups I-IV) of PH: mitral stenosis, congenital heart disease, chronic obstructive pulmonary lung disease, chronic thromboembolism, idiopathic pulmonary arterial hypertension (IPAH), familial (FPAH), collagen vascular disease, and methamphetamine exposure. X was calculated from pulmonary artery pressure (PPA), cardiac output (Q) and body weight (M), utilizing an allometric power-law prediction of X relative to a PH-free state. Comparisons of X between PAH-free and PAH subjects indicates a characteristic reduction in area that elevates arteriolar shear stress, which may contribute to mechanisms of endothelial dysfunction and injury before clinically defined thresholds of pulmonary vascular resistance and PH. We conclude that the evaluation of X may be of use in identifying reversible and irreversible phases of PH in the early course of the disease process.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  allometry; complexity; pulmonary hypertension

Mesh:

Year:  2014        PMID: 24858853      PMCID: PMC4121648          DOI: 10.1152/ajpheart.00144.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  42 in total

1.  A fractal continuum model of the pulmonary arterial tree.

Authors:  G S Krenz; J H Linehan; C A Dawson
Journal:  J Appl Physiol (1985)       Date:  1992-06

2.  Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension.

Authors:  Jan-Willem Lankhaar; Nico Westerhof; Theo J C Faes; C Tji-Joong Gan; Koen M Marques; Anco Boonstra; Fred G van den Berg; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2008-03-17       Impact factor: 29.983

3.  Structure-function relationships in the pulmonary arterial tree.

Authors:  C A Dawson; G S Krenz; K L Karau; S T Haworth; C C Hanger; J H Linehan
Journal:  J Appl Physiol (1985)       Date:  1999-02

4.  Role of arterial design on pulse wave reflection in a fractal pulmonary network.

Authors:  S H Bennett; B W Goetzman; J M Milstein; J S Pannu
Journal:  J Appl Physiol (1985)       Date:  1996-03

Review 5.  The metabolic basis of pulmonary arterial hypertension.

Authors:  Gopinath Sutendra; Evangelos D Michelakis
Journal:  Cell Metab       Date:  2014-02-06       Impact factor: 27.287

6.  Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy.

Authors:  M Rabinovitch; T Bothwell; B N Hayakawa; W G Williams; G A Trusler; R D Rowe; P M Olley; E Cutz
Journal:  Lab Invest       Date:  1986-12       Impact factor: 5.662

7.  CT measurement of main pulmonary artery diameter.

Authors:  P D Edwards; R K Bull; R Coulden
Journal:  Br J Radiol       Date:  1998-10       Impact factor: 3.039

8.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

9.  Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic?

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

10.  Epigenetic mechanisms of pulmonary hypertension.

Authors:  Gene H Kim; John J Ryan; Glenn Marsboom; Stephen L Archer
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

View more
  4 in total

1.  Temporal analysis of cardiovascular control and function following incomplete T3 and T10 spinal cord injury in rodents.

Authors:  Kathryn A Harman; Gregory States; Abigail Wade; Chad Stepp; Grace Wainwright; Kathryn DeVeau; Nicholas King; Alice Shum-Siu; David S K Magnuson
Journal:  Physiol Rep       Date:  2018-03

Review 2.  Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?

Authors:  Kondababu Kurakula; Valérie F E D Smolders; Olga Tura-Ceide; J Wouter Jukema; Paul H A Quax; Marie-José Goumans
Journal:  Biomedicines       Date:  2021-01-09

Review 3.  Endothelial Cell Mechano-Metabolomic Coupling to Disease States in the Lung Microvasculature.

Authors:  David Wu; Konstantin Birukov
Journal:  Front Bioeng Biotechnol       Date:  2019-07-19

Review 4.  Advances in the management of pulmonary arterial hypertension.

Authors:  Himanshu Deshwal; Tatiana Weinstein; Roxana Sulica
Journal:  J Investig Med       Date:  2021-10       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.